Trexquant Investment LP Raises Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Trexquant Investment LP increased its stake in Jazz Pharmaceuticals by 30.0% during the first quarter, now owning approximately 0.10% of the company valued at $7.95 million.
• Jazz Pharmaceuticals reported a loss of $8.25 EPS for the most recent quarter, missing expectations, although revenue saw a 2.1% year-over-year increase.
• Institutional investors hold 89.14% of Jazz Pharmaceuticals' stock, indicating strong interest from significant market players.

Trexquant Investment LP grew its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 30.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,078 shares of the specialty pharmaceutical company's stock after buying an additional 14,781 shares during the period. Trexquant Investment LP owned approximately 0.10% of Jazz Pharmaceuticals worth $7,955,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Nuveen LLC purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth $62,362,000. Fuller & Thaler Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after buying an additional 391,660 shares in the last quarter. Perpetual Ltd grew its stake in shares of Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after buying an additional 357,784 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ:JAZZ traded down $3.38 during trading hours on Thursday, hitting $128.34. The company's stock had a trading volume of 386,763 shares, compared to its average volume of 944,782. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -19.06, a P/E/G ratio of 8.04 and a beta of 0.24. The firm's fifty day moving average price is $115.82 and its 200 day moving average price is $117.12.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the firm posted $5.30 EPS. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently commented on JAZZ. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Robert W. Baird dropped their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.